MK-677

What it is

MK-677 (ibutamoren) is an orally bioavailable small-molecule ghrelin receptor agonist developed by Merck in the 1990s. Despite often being grouped with peptide GH secretagogues, MK-677 is technically not a peptide — it is a synthetic small molecule that mimics ghrelin’s effects on the GH-releasing pathway.

MK-677 was studied extensively by Merck in the 1990s and 2000s for GH deficiency, frailty in elderly populations, and various other indications. The development program was eventually discontinued. The compound was later licensed to Reata Pharmaceuticals (then Lumos Pharma) for development in pediatric GH deficiency, but has not received FDA approval for any indication.

Mechanism of action

MK-677 acts as a ghrelin receptor (GHS-R1a) agonist with effects similar to peptide GHRPs but with the practical advantage of oral bioavailability:

• Sustained GH and IGF-1 elevation: oral once-daily dosing produces continuous receptor activation, leading to sustained GH/IGF-1 elevation that approaches young-adult ranges in older patients
• Appetite stimulation: ghrelin-receptor activation stimulates appetite, often substantially
• Sleep effects: some users report deeper sleep, possibly mediated by GH effects on slow-wave sleep
• Long half-life: approximately 24 hours, supporting once-daily oral dosing

Clinical evidence

MK-677 has substantial clinical trial data from the Merck development program:

• Effects on GH/IGF-1 elevation are well-characterized and reliable
• Studies in elderly populations showed improvements in body composition (modest increases in lean mass)
• Studies in obese patients showed favorable effects on metabolism but with the caveat of appetite stimulation
• Trials in hip fracture recovery showed some benefits in functional outcomes

Why we don’t prescribe it at The Tide

Several factors lead us to prefer peptide-based GH-axis support over MK-677:

• Continuous vs. pulsatile signaling: MK-677 produces continuous GH/IGF-1 elevation rather than the pulsatile pattern preserved by sermorelin or CJC-1295 (no DAC) + ipamorelin protocols
• Appetite stimulation: often counterproductive for patients working on metabolic and weight goals
• Insulin resistance: sustained GH elevation can worsen insulin sensitivity in some patients
• Water retention and joint discomfort: rates higher than with pulsatile peptide approaches
• Not technically a peptide: MK-677 falls outside our peptide-focused practice scope

Patients seeking GH-axis support are better served by peptide protocols that preserve physiologic pulsatility.

Side effects and contraindications

Significant appetite stimulation, water retention, joint discomfort, possible insulin resistance with sustained use, fatigue in some patients, and long-term safety questions about sustained GH/IGF-1 elevation. Contraindicated in malignancy, pregnancy, severe diabetes, and active retinopathy.